» Articles » PMID: 22963441

P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential

Overview
Specialties Neurology
Pharmacology
Date 2012 Sep 12
PMID 22963441
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

P2Y receptors for extracellular nucleotides are coupled to activation of a variety of G proteins and stimulate diverse intracellular signaling pathways that regulate functions of cell types that comprise the central nervous system (CNS). There are 8 different subtypes of P2Y receptor expressed in cells of the CNS that are activated by a select group of nucleotide agonists. Here, the agonist selectivity of these 8 P2Y receptor subtypes is reviewed with an emphasis on synthetic agonists with high potency and resistance to degradation by extracellular nucleotidases that have potential applications as therapeutic agents. In addition, the recent identification of a wide variety of subtype-selective antagonists is discussed, since these compounds are critical for discerning cellular responses mediated by activation of individual P2Y receptor subtypes. The functional expression of P2Y receptor subtypes in cells that comprise the CNS is also reviewed and the role of each subtype in the regulation of physiological and pathophysiological responses is considered. Other topics include the role of P2Y receptors in the regulation of blood-brain barrier integrity and potential interactions between different P2Y receptor subtypes that likely impact tissue responses to extracellular nucleotides in the CNS. Overall, current research suggests that P2Y receptors in the CNS regulate repair mechanisms that are triggered by tissue damage, inflammation and disease and thus P2Y receptors represent promising targets for the treatment of neurodegenerative diseases.

Citing Articles

Purine and purinergic receptors in health and disease.

Ai Y, Wang H, Liu L, Qi Y, Tang S, Tang J MedComm (2020). 2023; 4(5):e359.

PMID: 37692109 PMC: 10484181. DOI: 10.1002/mco2.359.


Alterations of Purinergic Receptors Levels and Their Involvement in the Glial Cell Morphology in a Pre-Clinical Model of Autism Spectrum Disorders.

Babiec L, Wilkaniec A, Matuszewska M, Palasz E, Cieslik M, Adamczyk A Brain Sci. 2023; 13(7).

PMID: 37509018 PMC: 10377192. DOI: 10.3390/brainsci13071088.


Structural insights into signal transduction of the purinergic receptors P2Y1R and P2Y12R.

Li B, Han S, Wang M, Yu Y, Ma L, Chu X Protein Cell. 2023; 14(5):382-386.

PMID: 37155313 PMC: 10166156. DOI: 10.1093/procel/pwac025.


The P2X7 Receptor as a Mechanistic Biomarker for Epilepsy.

Engel T Int J Mol Sci. 2023; 24(6).

PMID: 36982485 PMC: 10049244. DOI: 10.3390/ijms24065410.


Altered purinergic receptor expression in the frontal cortex in schizophrenia.

Alnafisah R, Lundh A, Asah S, Hoeflinger J, Wolfinger A, Hamoud A Schizophrenia (Heidelb). 2022; 8(1):96.

PMID: 36376358 PMC: 9663420. DOI: 10.1038/s41537-022-00312-1.


References
1.
Chorna N, Santiago-Perez L, Erb L, Seye C, Neary J, Sun G . P2Y receptors activate neuroprotective mechanisms in astrocytic cells. J Neurochem. 2004; 91(1):119-32. DOI: 10.1111/j.1471-4159.2004.02699.x. View

2.
Chang K, Hanaoka K, Kumada M, Takuwa Y . Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J Biol Chem. 1995; 270(44):26152-8. DOI: 10.1074/jbc.270.44.26152. View

3.
Erb L, Liu J, Ockerhausen J, Kong Q, Garrad R, Griffin K . An RGD sequence in the P2Y(2) receptor interacts with alpha(V)beta(3) integrins and is required for G(o)-mediated signal transduction. J Cell Biol. 2001; 153(3):491-501. PMC: 2190579. DOI: 10.1083/jcb.153.3.491. View

4.
Ruan H, Burnstock G . Localisation of P2Y1 and P2Y4 receptors in dorsal root, nodose and trigeminal ganglia of the rat. Histochem Cell Biol. 2003; 120(5):415-26. DOI: 10.1007/s00418-003-0579-3. View

5.
Degagne E, Grbic D, Dupuis A, Lavoie E, Langlois C, Jain N . P2Y2 receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells. J Immunol. 2009; 183(7):4521-9. PMC: 3613989. DOI: 10.4049/jimmunol.0803977. View